Search clinical trials for: Cetuximab Injection [Erbitux]

Total 12615 results

AVEO Pharmaceuticals, Inc.

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia
Pierre Fabre Medicament
Pfizer; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd

Completed

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC)

BRAF V600E-mutant Metastatic Colorectal Cancer

France, Italy, United States, Spain, United Kingdom, Belgium, Austria, Japan, Netherlands
NKGen Biotech, Inc.

Withdrawn

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Sarcoma | Cervical Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | EGF-R Positive Non-Small... and other conditions
UNICANCER

Terminated

Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss (COPAN-ORL06)

Carcinoma, Squamous Cell of Head and Neck

France
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Merck Sharp & Dohme LLC

Unknown

Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance (I-Tackle)

Skin Neoplasm

Italy
Martin Schuler, Prof. Dr. med.

Completed

Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer (CEBIFOX)

Metastatic Colorectal Cancer

Germany
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer

Endometrial Cancer

United States
University of Chicago
Verastem, Inc.

Recruiting

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Advanced Colorectal Carcinoma | Advanced Colorectal Adenocarcinoma

United States
Trans Tasman Radiation Oncology Group

Completed

Chemoradiation Treatment for Head and Neck Cancer

Head and Neck Cancer

Australia
Presage Biosciences
Takeda

Completed

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Head and Neck Cancer

United States
Georgetown University
GlaxoSmithKline

Completed

Lapatinib and Cetuximab in Patients With Solid Tumors (TYKERB-ITUX 1)

Head and Neck Cancer | Colorectal Cancer | Lung Cancer

United States
RenJi Hospital

Active, not recruiting

Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer

Rectal Cancer Stage III

China
Institute of Oncology Ljubljana

Unknown

Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer (XERT)

Rectal Cancer

Slovenia
M.D. Anderson Cancer Center
Eli Lilly and Company; BioMed Valley Discoveries, Inc

Recruiting

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Metastatic Colorectal Cancer

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Colorectal Neoplasms

Spain, United States, France, Italy, Belgium, Czechia, United Kingdom, Russian Federation
Merck KGaA, Darmstadt, Germany
Merck Pte. Ltd., Singapore

Completed

Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) (APEC)

Metastatic Colorectal Cancer

Singapore
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma

United States
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma.

Adenocarcinoma of Stomach

China
Fate Therapeutics

Completed

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | HER2 Positive Gastric Cancer | EGFR Positive Solid Tumor

United States
UNICANCER

Completed

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

France
Boehringer Ingelheim

Completed

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

Neoplasms

France, Spain
Amgen

Completed

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Sweden, Belgium, Czechia, Italy, Poland, United States, France, Korea, Republic of, Peru, Philippines, Russian Federation, United Kingdom, China, Canada, Israel, Lithuania, Australia, South Africa, Bulgaria, Romania, Taiwan, Latvia, Serbi... and more
Gilead Sciences
California Institute for Regenerative Medicine (CIRM)

Completed

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Colorectal Cancer | Solid Tumor

United States
Georgetown University

Withdrawn

Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer (PGx-SELECT)

Head and Neck Cancer
US Oncology Research
Eli Lilly and Company; Sanofi

Completed

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

Gastric Cancer Adenocarcinoma Metastatic

United States
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

Colorectal Cancer

United States, Australia, Austria, Belgium, Czech Republic, Finland, France, Germany, Hong Kong, Italy, Netherlands, Norway, Portugal, Slovakia, Sweden, Switzerland, United Kingdom
K-Group, Beta, Inc., a wholly owned subsidiary...
Pfizer

Recruiting

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Spain, Australia, United States, Italy, Germany, Poland, Hungary
University of California, Davis
National Cancer Institute (NCI)

Completed

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
The Methodist Hospital Research Institute
Bristol-Myers Squibb; Eli Lilly and Company

Terminated

Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy

Prostatic Neoplasms

United States
EMD Serono

Completed

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck Cancer

Czech Republic, France, United Kingdom, Belgium, Hungary, United States, Poland, Slovakia
University of Heidelberg Medical Center
iOMEDICO AG

Completed

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) (HICARE)

Head and Neck Cancer

Germany
Swiss Group for Clinical Cancer Research

Completed

Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer

Prostate Cancer

Switzerland
American Scitech International
Bristol-Myers Squibb; Eli Lilly and Company

Withdrawn

Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma

Colorectal Carcinoma

United States
R-Pharm

Completed

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
Asan Medical Center

Completed

Study of XELOX With Cetuximab in Advanced Gastric Cancer

Gastric Cancer

Korea, Republic of
Eli Lilly and Company

Completed

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States
Yale University
Boehringer Ingelheim; National Comprehensive Cancer Network

Recruiting

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Squamous Cell Cancers of the Head and Neck

United States
Eli Lilly and Company

Completed

Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

Neoplasms

United States
Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed

Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN (HNO-2)

Squamous Cell Carcinoma of the Hypopharynx Stage III | Squamous Cell Carcinoma of the Hypopharynx Stage IV | Squamous Cell Carcinoma of the Larynx Stage III | Squamous Cell Carcinoma of the Larynx Stage IV | Squamous Cell Carcinoma of the Oropharynx Stage III | Squamous Cell Carcinoma of the... and other conditions

Austria
Eli Lilly and Company

Completed

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

Head and Neck Neoplasms

United States, France
Sun Yat-sen University

Recruiting

Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy

Metastatic Colorectal Cancer

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Sanofi; Roche Pharma AG; National...

Completed

Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer (NRR)

Liver Cancer

United States
Nanobiotix

Recruiting

NBTXR3 With or Without Cetuximab in LA-HNSCC

Aged | Locally Advanced Head and Neck Squamous Cell Carcinoma

France, Spain, Israel, United States, Taiwan, Finland, Japan, Belgium, Korea, Republic of, Hungary, China, Georgia, Portugal, Austria, Bulgaria, Canada, Czechia, Germany, Greece, Romania, Serbia
Shanghai Jiao Tong University School of Medicine
Fudan University; Tongji University; Second Military Medical University

Completed

Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer

Oral Cancer | Locally Advanced Malignant Neoplasm | Oropharyngeal Carcinoma

China
Novartis Pharmaceuticals

Terminated

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

France, Taiwan, United States, Australia, Canada, Hong Kong, Singapore, Korea, Republic of, Netherlands
Hospices Civils de Lyon

Terminated

Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases

Neoplasm Metastasis | Colorectal Cancer

France
University of Maryland, Baltimore
Bristol-Myers Squibb

Completed

Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)

Cancer of Head and Neck

United States
Enzon Pharmaceuticals, Inc.

Unknown

A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

Metastatic Colorectal Cancer

United States, Canada, Israel, Netherlands, United Kingdom
Xu jianmin

Unknown

Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer

Neoplasm Metastasis | Liver Neoplasms | Colorectal Neoplasms

China

Search clinical trials for: Cetuximab Injection [Erbitux]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations